Stem Cell Therapy for Pain - Now Available at Columbia Pain Management
http://regenerativepaintherapy.com Call: 541-716-6469 Columbia Pain Management Can Help You Get Your Life Back. Stem Cell Therapy for Pain - Now Available at Columbia Pain Management.
By: Trey Rigert
Read more from the original source:
Stem Cell Therapy for Pain - Now Available at Columbia Pain Management - Video
New Delhi, April 11 (IANS): Though there are many stem cell therapies that are being explored, bone marrow transplant is the only one which has been tried and tested, a noted scientist has said.
Stem cell therapy is the use of stem cells to treat or prevent a disease or condition. Stem cells are undifferentiated cells of an organism which are capable of giving rise to indefinitely more cells of the same type, and from which certain other kinds of cells arise by differentiation.
"Most of the stem cell therapies like the ones which can successfully treat Parkinson's disease and methods of ortho-reconstruction are in experimental stages," noted cellular biologist Jyotsna Dhawan said in a special lecture on 'Stem cells: Myths and Realities' at the India International Centre (IIC) here Friday evening.
Dhawan, a senior scientist at the Centre for Cellular and Molecular Biology, Hyderabad, said stem cells are a potential source of repair of other tissues and can be very useful in treating genetic and inherited diseases. She said stem cells are specially useful in treating genetic disorders associated with blood like haemophilia and thalassemia.
"But, major ethical issues arise when embryonic stem cells (cells taken from a foetus) are used for therapy," she added.
On the many myths associated with stem cells, Dhawan said: "All these myths stem from the hope that we are able to tackle many of these diseases through stem cells".
Experiments are on to try and find cures for debilitating and terminal diseases like muscular dystrophy and cancer through stem cell therapy.
Stay updated wherever you go with Daijiworld.com and Daijiworld 24X7 tv channel mobile apps. CLICK HERE to download it for your device. (available on Android and IOS)
Read this article:
Most stem cell therapy at experimental stage: Scientist
The New Botox: Stem Cell Therapy Cream Reviews- Wellington Anti Aging Centre Loxahatchee FL
The New Botox: Stem Cell Therapy Cream Reviews http://GoAgelessNow.com The New Botox: Stem Cell Therapy Cream Reviews Stem cell therapy is the use of stem cells to treat or prevent a disease.
By: Jamal Spikes
Link:
The New Botox: Stem Cell Therapy Cream Reviews- Wellington Anti Aging Centre Loxahatchee FL - Video
Degenerated Discs/Shoulder Arthritis 7 months after stem cell treatment by Harry Adelson, N.D.
Len describes his outcome seven months after fat-derrived stem cell treatment by Harry Adelson N.D. for his degenerated lumbar discs and arthritic shoulders http://www.docereclinics.com.
By: Harry Adelson, N.D.
U.S. Stem Cell Clinic: Stem Cell Banking
The U.S. Stem Cell Clinic is founded on the principle belief that the quality of life for our patients can be improved through stem cell therapy. We are dedicated to providing safe and effective...
By: U.S. Stem Cell Clinic
Go here to read the rest:
U.S. Stem Cell Clinic: Stem Cell Banking - Video
U.S. Stem Cell Clinic: How long will my recovery take?
Our U.S. Stem Cell Clinic procedure is minimally invasive and patients walk out within 3 hours in most cases. As a result recovery time is very quick. Many patients will experience soreness...
By: U.S. Stem Cell Clinic
Read more here:
U.S. Stem Cell Clinic: How long will my recovery take? - Video
U.S. Stem Cell Clinic: How is Stem Cell Therapy Performed?
Our U.S. Stem Cell Clinic will perform outpatient procedures using a process in which we isolate a patient #39;s own stem cells from either their own adipose fat tissue or bone marrow. Approximately...
By: U.S. Stem Cell Clinic
Continue reading here:
U.S. Stem Cell Clinic: How is Stem Cell Therapy Performed? - Video
U.S. Stem Cell Clinic: What is Stem Cell Therapy?
What is Stem Cell Therapy? Stem cell therapy attempts to harness the body #39;s own healing potential by isolating stem cells from one location of the body (fat tissue or bone marrow) and relocating...
By: U.S. Stem Cell Clinic
Read the original here:
U.S. Stem Cell Clinic: What is Stem Cell Therapy? - Video
U.S. Stem Cell Clinic: When should I expect to see results?
It is important to note that we are treating patients with their own adult stem cells, therefore each treatment and response is unique to that patient. No guarantee can be made of what results...
By: U.S. Stem Cell Clinic
Read the original here:
U.S. Stem Cell Clinic: When should I expect to see results? - Video
Using induced pluripotent stem cells (iPSCs), a team led by Mount Sinai researchers has gained new insight into genetic changes that may turn a well known anti-cancer signaling gene into a driver of risk for bone cancers, where the survival rate has not improved in 40 years despite treatment advances.
The study results, published today in the journal Cell, revolve around iPSCs, which since their 2006 discovery have enabled researchers to coax mature (fully differentiated) bodily cells (e.g. skin cells) to become like embryonic stem cells. Such cells are pluripotent, able to become many cell types as they multiply and differentiate to form tissues. The iPSCs can then be converted again as needed into differentiated cells such as heart muscle, nerve cells, bone, etc.
While some seek to use iPSCs as replacements for cells compromised by disease, the new Mount Sinai study sought to determine if they could serve as an accurate model of genetic disease "in a dish." In this context, the dish stands for a self-renewing, unlimited supply of iPSCs or a cell line - which enables in-depth study of disease versions driven by each person's genetic differences. When matched with patient records, iPSCs and iPSC-derived target cells may be able to predict a patient's prognosis and whether or not a given drug will be effective for him or her.
In the current study, skin cells from patient with and without disease were turned into patient-specific iPSC lines, and then differentiated into bone-making cells where both rare and common bone cancers start. This new bone cancer model does a better job than previously used mouse or cellular models of "recapitulating" the features of bone cancer cells driven by key genetic changes.
"Our study is among the first to use induced pluripotent stem cells as the foundation of a model for cancer," said lead author Dung-Fang Lee, PhD, a postdoctoral fellow in the Department of Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai. "This model, when combined with a rare genetic disease, revealed for the first time how a protein known to prevent tumor growth in most cases, p53, may instead drive bone cancer when genetic changes cause too much of it to be made in the wrong place."
Rare Disease Sheds Light on Common Disease
The Mount Sinai disease model research is based on the fact that human genes, the DNA chains that encode instructions for building the body's structures and signals, randomly change all the time. As part of evolution, some code changes, or mutations, make no difference, some confer advantages, and others cause disease. Beyond inherited mutations that contribute to cancer risk, the wrong mix of random, accumulated DNA changes in bodily (somatic) cells as we age also contributes to cancer risk.
The current study focused on the genetic pathways that cause a rare genetic disease called Li-Fraumeni Syndrome or LFS, which comes with high risk for many cancers in affected families. A common LFS cancer type is osteosarcoma (bone cancer), with many diagnosed before the age of 30. Beyond LFS, osteosarcoma is the most common type of bone cancer in all children, and after leukemia, the second leading cause of cancer death for them.
Importantly, about 70 percent of LFS families have a mutation in their version of the gene TP53, which is the blueprint for protein p53, well known by the nickname "the tumor suppressor." Common forms of osteosarcoma, driven by somatic versus inherited mutations, have also been closely linked by past studies to p53 when mutations interfere with its function.
Rare genetic diseases like LFS are good study models because they tend to proceed from a change in a single gene, as opposed to many, overlapping changes seen in more related common diseases, in this case more common, non-inherited bone cancers. The LFS-iPSC based modeling highlights the contribution of p53 alone to osteosarcoma.
See the rest here:
Stem cell disease model clarifies bone cancer trigger